aTYR PHARMA INC
Close on Oct 19, 2026
- Market cap
- $16.84M
- P/E (TTM)
- –
- Dividend yield
- –
About aTYR PHARMA
Biological Products, (No Diagnostic Substances), SIC 2836
aTyr Pharma, Inc. is a clinical-stage biotechnology company that utilizes evolutionary intelligence to translate tRNA synthetase biology into therapies for fibrosis and inflammation. Its discovery platform identifies signaling pathways driven by domains derived from all twenty tRNA synthetases to unlock potential therapeutic intervention points. The company's lead therapeutic candidate is efzofitimod, a biologic immunomodulator designed to treat interstitial lung diseases such as pulmonary sarcoidosis and systemic sclerosis-associated interstitial lung disease. Additionally, the company develops pipeline candidates including ATYR0101 for fibrotic diseases and ATYR0750 for inflammatory and fibrotic conditions.
The company operates in the United States and has an international collaboration with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod in Japan. It also maintains a subsidiary, Pangu BioPharma Limited, in Hong Kong. aTyr Pharma is headquartered in San Diego, California.
Summary of the business section of aTYR PHARMA's latest annual report, written by StockData.
Company profile
Company
- Legal name
- aTYR PHARMA INC
- Founded
- 2005
- Headquarters
- San Diego, CA
- Address
- 10240 Sorrento Valley Road, Suite 300 92121
- Phone
- (858) 731-8389
- Website
- atyrpharma.com
- Employees
- 58, Dec 31, 2025
- Industry
- Biological Products, (No Diagnostic Substances)
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Ernst & Young LLP, San Diego, California
Stock & identifiers
- Ticker
- ATYR
- Exchange
- Nasdaq
- IPO date
- May 7, 2015
- Shares outstanding
- 98M, Jul 31, 2026
- Public float
- $463.82M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-14 reverse, Aug 14, 2019; 1-for-14 reverse, Jul 1, 2019
- SEC CIK
- 1339970
- CUSIP
- 002120202
- ISIN
- US0021202025
- LEI
- 529900ENQUXMC5EBKO36
- EIN
- 20-3435077
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Sanjay Shukla | President and CEO, Director | 153,553 |
| Jill Marie Broadfoot | Chief Financial Officer | 37,296 |
| Nancy Denyes | General Counsel | 33,124 |
| Paul Schimmel | Director | 2,201,056 |
| Svetlana Lucas | Director | 6,000 |
| Sara Zaknoen | Director | 6,000 |
| Eric Benevich | Director | – |
| Timothy Coughlin | Director | 56,000 |
| Jane A. Gross | Director | 9,750 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Dr. Shukla | $3.46M | $575.97K | $1.30M | $36 | – |
| FY2024 Dr. Shukla | $1.48M | $3.14M | $737.73K | $165 | – |
| FY2023 Dr. Shukla | $1.30M | $596.67K | $664.56K | $64 | – |
| FY2022 Dr. Shukla | $2.41M | $480.85K | $885.51K | $29 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 58 employees, 56 of which were full-time employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Jun 8, 2026 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Dec 5, 2025 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Feb 8, 2019 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Aug 14, 2018 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| May 7, 2015 | IPO | Initial public offering priced (424B4 prospectus) |
| May 6, 2015 | Listing | Registration of securities on an exchange (Form 8-A) |